Livzon Pharmaceutical Group Statistics
Livzon Pharmaceutical Group (LVZPF) Stock Statistics & Valuation Metrics
Total Valuation
Livzon Pharmaceutical Group has a market cap or net worth of $3.75B. The enterprise value is $17.84B.
- Market Cap
- $3.75B
- Enterprise Value
- $17.84B
Share Statistics
Livzon Pharmaceutical Group has 299,807,130 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 299,807,130
- Owned by Insiders
- ―
- Owned by Institutions
- 5.92%
Financial Efficiency
Livzon Pharmaceutical Group’s return on equity (ROE) is 0.15 and return on invested capital (ROIC) is 12.50%.
- Return on Equity (ROE)
- 0.15
- Return on Assets (ROA)
- 0.08
- Return on Invested Capital (ROIC)
- 12.50%
- Return on Capital Employed (ROCE)
- 0.18
- Revenue Per Employee
- 1.35M
- Profits Per Employee
- 227.89K
- Employee Count
- 8,878
- Asset Turnover
- 0.50
- Inventory Turnover
- 2.62
Valuation Ratios
The current PE Ratio of Livzon Pharmaceutical Group is 18.10. Livzon Pharmaceutical Group’s PEG ratio is -0.67.
- PE Ratio
- 18.10
- PS Ratio
- 2.45
- PB Ratio
- 2.16
- Price to FCF
- 9.06
- Price to Operating Cash Flow
- 8.86
- PEG Ratio
- -0.67
Income Statement
In the last 12 months, Livzon Pharmaceutical Group had revenue of 12.02B and earned 2.02B in profits. Earnings per share was 2.27.
- Revenue
- 12.02B
- Gross Profit
- 7.92B
- Operating Income
- 2.95B
- Pretax Income
- 2.86B
- Net Income
- 2.02B
- EBITDA
- 3.10B
- Earnings Per Share (EPS)
- 2.27
Cash Flow
In the last 12 months, operating cash flow was 3.20B and capital expenditures -414.85M, giving a free cash flow of 2.79B billion.
- Operating Cash Flow
- 3.20B
- Free Cash Flow
- 2.79B
- Free Cash Flow per Share
- 3.11
Dividends & Yields
Livzon Pharmaceutical Group pays an annual dividend of $0.21, resulting in a dividend yield of 3.86%
- Dividend Per Share
- $0.21
- Dividend Yield
- 3.86%
- Payout Ratio
- 65.69%
- Free Cash Flow Yield
- 11.04%
- Earnings Yield
- 5.54%
Stock Price Statistics
- Beta
- 0.29
- 52-Week Price Change
- -27.22%
- 50-Day Moving Average
- 3.72
- 200-Day Moving Average
- 3.79
- Relative Strength Index (RSI)
- 99.97
- Average Volume (3m)
- ―
Important Dates
Livzon Pharmaceutical Group upcoming earnings date is Mar 31, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Oct 23, 2026
- Next Earnings Date
- Mar 31, 2027
- Ex-Dividend Date
- Jun 17, 2026
Financial Position
Livzon Pharmaceutical Group as a current ratio of 2.23, with Debt / Equity ratio of 27.69%
- Current Ratio
- 2.23
- Quick Ratio
- 2.02
- Debt to Market Cap
- 0.17
- Net Debt to EBITDA
- -1.76
- Interest Coverage Ratio
- 48.99
Taxes
In the past 12 months, Livzon Pharmaceutical Group has paid 451.01M in taxes.
- Income Tax
- 451.01M
- Effective Tax Rate
- 0.16
Enterprise Valuation
Livzon Pharmaceutical Group EV to EBITDA ratio is 9.38, with an EV/FCF ratio of 7.95.
- EV to Sales
- 2.15
- EV to EBITDA
- 9.38
- EV to Free Cash Flow
- 7.95
- EV to Operating Cash Flow
- 6.92
Balance Sheet
Livzon Pharmaceutical Group has $7.31B in cash and marketable securities with $4.20B in debt, giving a net cash position of $3.11B billion.
- Cash & Marketable Securities
- $7.31B
- Total Debt
- $4.20B
- Net Cash
- $3.11B
- Net Cash Per Share
- $10.38
- Tangible Book Value Per Share
- $13.70
Margins
Gross margin is 60.53%, with operating margin of 19.25%, and net profit margin of 15.23%.
- Gross Margin
- 60.53%
- Operating Margin
- 19.25%
- Pretax Margin
- 21.50%
- Net Profit Margin
- 15.23%
- EBITDA Margin
- 22.91%
- EBIT Margin
- 19.83%
Analyst Forecast
The average price target for Livzon Pharmaceutical Group is $4.37, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- $4.37
- Price Target Upside
- 14.95% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 2
- Revenue Growth Forecast
- -9.78%
- EPS Growth Forecast
- -23.43%
Scores
- Smart Score
- 7
- AI Score
- ―

